| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/18/2001 | US6290948 Using certain chemokines or biologically active fragments thereof alone or in conjunction with an anti-infective agent or hematopoietic maturing agent. |
| 09/18/2001 | US6290929 Cancer treatment |
| 09/18/2001 | US6289892 Partial liquid breathing of fluorocarbons |
| 09/18/2001 | CA2238879C Thereapeutic applications for the anti-t-bam (cd40-l) monoclonal antibody 5c8 |
| 09/18/2001 | CA2145182C Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| 09/18/2001 | CA1341292C The manufacture and expression of consensus human leukocyte interferon |
| 09/13/2001 | WO2001067107A1 Modulation of histone deacetylase |
| 09/13/2001 | WO2001066714A1 α-AMYLASE ACTIVITY INHIBITORS |
| 09/13/2001 | WO2001066706A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066698A1 Human cord blood as a source of neural tissue for repair of the brain and spinal cord |
| 09/13/2001 | WO2001066599A1 Crystal |
| 09/13/2001 | WO2001066595A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066594A2 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | WO2001066564A2 Gamma-secretase inhibitors |
| 09/13/2001 | WO2001066557A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066553A2 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 09/13/2001 | WO2001066544A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | WO2001066540A1 Imidazol-2-carboxamide derivatives as raf kinase inhibitors |
| 09/13/2001 | WO2001066539A1 Imidazol derivatives as raf kinase inhibitors |
| 09/13/2001 | WO2001066533A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | WO2001066531A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 09/13/2001 | WO2001066525A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | WO2001066521A1 Azacyclic compounds for use in the treatment of serotonin related diseases |
| 09/13/2001 | WO2001066143A1 Vasoactive agents |
| 09/13/2001 | WO2001066141A1 Remedies and preventives for antiphospholipid antibody syndrome |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066139A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 09/13/2001 | WO2001066137A1 Adenovirus formulations |
| 09/13/2001 | WO2001066133A1 Leptin-resistance ameliorating agents |
| 09/13/2001 | WO2001066132A2 Hiv immune adjuvant therapy |
| 09/13/2001 | WO2001066131A1 Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase |
| 09/13/2001 | WO2001066125A1 DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
| 09/13/2001 | WO2001066124A2 Composition for the treatment of heart failure |
| 09/13/2001 | WO2001066123A2 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | WO2001066121A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 09/13/2001 | WO2001066112A1 Urease inhibitors |
| 09/13/2001 | WO2001066110A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066100A2 Pharmaceutical composition |
| 09/13/2001 | WO2001066099A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 09/13/2001 | WO2001066098A2 Therapeutic uses of ppar mediators |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001030759A3 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028993A3 Tyrosine kinase inhibitors |
| 09/13/2001 | WO2001028498A3 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 09/13/2001 | WO2001028497A3 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 09/13/2001 | WO2001016288A3 Dna encoding the human serine protease c-e |
| 09/13/2001 | WO2001015733A3 Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction |
| 09/13/2001 | WO2001009138A3 Chemokine receptor antagonists and methods of use therefor |
| 09/13/2001 | WO2001004282A3 Replication-competent anti-cancer vectors |
| 09/13/2001 | WO2000063370A3 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 09/13/2001 | WO2000039347A9 A tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein |
| 09/13/2001 | US20010021791 Cyclopropyl phenyl ketone compound |
| 09/13/2001 | US20010021777 Indane or dihydroindole derivatives |
| 09/13/2001 | US20010021772 Vascular endothelial growth factor |
| 09/13/2001 | US20010021758 Drugs, medical diagnosis |
| 09/13/2001 | US20010021723 Histochrome and its therapeutic use in ophthalmology |
| 09/13/2001 | US20010021722 Pharmaceutical compositions comprising monoamine oxidase b inhibitors |
| 09/13/2001 | US20010021720 Synergistic mixture of docletaxel and phosphodiesterase inhibitor |
| 09/13/2001 | US20010021717 Hydroxylation activated prodrugs |
| 09/13/2001 | US20010021716 Using agonist of nicotinergic acetylcholine receptors |
| 09/13/2001 | US20010021712 Antihistamines, antiallergens, brochodilator agents and antispasmodic agents |
| 09/13/2001 | US20010021708 Acylurea compound containing imidazolidine ring |
| 09/13/2001 | US20010021705 Inhibition of human bone loss |
| 09/13/2001 | US20010021704 Active compounds with cytostatic activity, biological electron acceptors, and pharmaceutically customary additives |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021400 Tanacetum parthenium extract and method of obtaining same |
| 09/13/2001 | DE10010113A1 Isolation of collagen by extraction from sponge, giving product having cyclooxygenase inhibiting activity, useful for treating inflammatory diseases such as arthritis or skin inflammation |
| 09/13/2001 | CA2799545A1 Adenovirus formulations |
| 09/13/2001 | CA2402466A1 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | CA2402315A1 Therapeutic uses of ppar mediators |
| 09/13/2001 | CA2402179A1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | CA2402096A1 Vasoactive agents |
| 09/13/2001 | CA2402081A1 A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
| 09/13/2001 | CA2402024A1 Hiv immune adjuvant therapy |
| 09/13/2001 | CA2401953A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 09/13/2001 | CA2401706A1 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 09/13/2001 | CA2401541A1 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | CA2401525A1 Gamma-secretase inhibitors |
| 09/13/2001 | CA2401524A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | CA2401398A1 Dna encoding human acid-sensing ion channel bnac4 (asic4) |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2401055A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | CA2400711A1 Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2400527A1 Urease inhibitors |
| 09/13/2001 | CA2400504A1 Composition for the treatment of heart failure |
| 09/13/2001 | CA2399921A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399913A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2372931A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 09/12/2001 | EP1132472A1 Novel protein and utilization thereof |
| 09/12/2001 | EP1132469A2 Methods for separating nucleic acids from Protein-nucleic acids complexes |
| 09/12/2001 | EP1132403A1 Tgf g beta1 inhibitor peptides |
| 09/12/2001 | EP1132390A2 Diazepinoindoles as phophodiesterase inhibitors |
| 09/12/2001 | EP1132388A2 Hexahydropyrazolo[4,3-c]pyridine metabolites |
| 09/12/2001 | EP1132380A1 E-Isomeric fullerene derivatives |
| 09/12/2001 | EP1132098A1 Gene therapy for cerebrovascular disorders |
| 09/12/2001 | EP1132090A1 Method for producing an agent for treating non-cancerous pathologies of the organism |
| 09/12/2001 | EP1132089A1 Extract from loquat seeds against fibrosis |